# **Supplement 6. Heterogeneity statistics in the meta-analyses.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Univariate analysis** | | | | **Moderator analysis** | | | |
| **Enabler** | **# of studies** |  |  | **Q-statistic** | **p-value** |  |  | **Q-statistic** | **p-value** |
| Relationship with clinical staff | 7 | 0.93 | 95.32 | 187.90 | <0.001 | 0.29 | 59.95 | 18.62 | 0.002 |
| Information provided | 11 | 1.96 | 98.94 | 1374.39 | <0.001 | 1.81 | 98.63 | 636.18 | <0.001 |
| Placebo/sham use | 12 | 1.45 | 98.78 | 366.67 | <0.001 | 1.37 | 98.70 | 364.15 | <0.001 |
| Disruption in current medication | 2 | - | - | - | - | - | - | - | - |
| Side effects | 19 | 1.52 | 98.50 | 1570.33 | <0.001 | 1.40 | 98.09 | 1239.86 | <0.001 |
| Visiting scheme | 5 | 1.76 | 98.06 | 397.30 | <0.001 | 1.19 | 96.10 | 166.67 | <0.001 |
| Clinic reputation | 9 | 1.37 | 97.16 | 403.46 | <0.001 | 1.26 | 96.81 | 386.15 | <0.001 |
| Travel burden | 15 | 1.25 | 97.25 | 768.99 | <0.001 | 1.19 | 96.67 | 682.09 | <0.001 |
| Awareness | 4 | 1.24 | 94.89 | 64.74 | <0.001 | 1.25 | 81.41 | 43.68 | <0.001 |
| HCP recommendation | 15 | 1.53 | 98.07 | 695.51 | <0.001 | 1.10 | 96.41 | 263.05 | <0.001 |
| Home-based assessments | 2 | - | - | - | - | - | - | - | - |
| Time consumption | 17 | 1.31 | 96.76 | 830.37 | <0.001 | 1.17 | 95.72 | 595.09 | <0.001 |
| Financial compensation | 13 | 0.89 | 94.86 | 220.64 | <0.001 | 0.85 | 93.93 | 212.38 | <0.001 |
| Invasiveness | 6 | 0.55 | 84.39 | 47.31 | <0.001 | 0.47 | 64.16 | 21.36 | <0.001 |
| Assessment burden | 8 | 1.89 | 95.14 | 213.82 | <0.001 | 1.73 | 93.59 | 200.90 | <0.001 |

The Q-statistic is based on a likelihood ratio test statistic with *k*-1 degrees of freedom (*k* is number of studies). No heterogeneity statistics are reported for meta-analyses with *k <* 3.